BioView Reports Encouraging Interim Results of Lung Cancer Diagnostic Test
Israel-based laboratory equipment developer BioView has reported positive results of its internal clinical trial of the non-invasive diagnostic test under development for early detection of lung cancer.
In the trial, a total of 76 sputum samples were collected from four groups of patients, healthy individuals that never smoked, heavy smokers with no signs of lung cancer, early stage lung cancer patients (stage 1) and advanced stage lung cancer patients.
The sputum samples were blindly scanned and analyzed morphologically and genetically, with fluorescent probes exclusively licensed to BioView, on BioView’s automated Duet scanning station by company personnel.
The results of the test were classified as ‘normal’(no cancer detected) and ‘abnormal’(cancer detected). These results were then compared to the actual data received from the hospital of the patients’ condition.
The samples included 32 cases of lung cancer patients and 44 samples taken from people with no clinical evidence of lung cancer. Approximately 31 of 32 (96.9%) sick patients were correctly diagnosed as ‘abnormal’ and 36 of 44 (about 82%) healthy people were correctly diagnosed as ‘normal’.
Opher Shapira, CEO of BioView, said: “We are extremely pleased with the results; the specificity and sensitivity in this test are better than other non-invasive tests presently available for early lung cancer detection. We are accelerating our development efforts to improve these results as well as to increase our sample size and to include other laboratories in the clinical trials.”